Return to search

Versant Ventures commits $30m to Matterhorn Biosciences

Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies.

Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies. Versant has committed $30 million to Matterhorn.

Source: Press Release